RenovoRx (RNXT) investor relations material

Company overview and technology

• Focuses on improving cancer therapy by delivering high local drug concentrations while minimizing systemic toxicity, using the FDA-cleared RenovoCath device and TAMP platform.

• Device is commercially available in 16 active centers as of May, with strong physician interest and expanding applications beyond pancreatic cancer.

• TAMP platform enables targeted delivery, achieving up to 100x local drug concentration and 50% reduction in systemic exposure in animal studies.

• Outpatient procedure is minimally invasive, requires limited physician training, and is well tolerated by patients.

• Expansion opportunities include other tumor types such as cholangiocarcinoma, non-small cell lung cancer, glioblastoma, sarcomas, and uterine tumors.

Commercial strategy and financial outlook

• Commercial launch driven by physician demand, with reimbursement in place and a targeted sales approach focused on top cancer centers.

• Achieved over $1 million in 2025 revenue, with $560,000 in Q1 2026 and guidance for higher Q2 revenue.

• Pipeline includes 16 active centers and 32 in evaluation, aiming for 36 active commercial sites by year-end.

• Business model targets $400 million peak revenue, high gross margins (85-90%), and break-even expected in the second half of next year.

• Well-capitalized with $12.4 million in cash at Q1 end, supporting growth and limited need for additional financing.

Clinical development and data

• Phase III TIGeR-PaC trial nearing enrollment completion, evaluating intra-arterial gemcitabine for locally advanced pancreatic cancer.

• Interim data show a six-month survival increase and 65% reduction in toxicities compared to standard of care.

• Final data expected mid to late next year, with potential for significant survival benefit and improved quality of life.

• Investigator-initiated trials expanding into borderline and metastatic pancreatic cancer, as well as other tumor types.

• Orphan Drug Designations awarded for multiple indications, supporting regulatory and commercial strategy.